Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines.

Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines.
复制标题

伊马替尼甲酸酯(Gleevec)下调端粒酶活性,并抑制表达端粒酶的细胞系中的增殖。

DOI:
10.1038/sj.bjc.6602592
复制
发表时间:
2005-05-23
影响因子:
8.8
通讯作者:
Lahav, M
Lahav, M
中科院分区:
医学1区
文献类型:
--
作者:
Uziel, O;Fenig, E;Nordenberg, J;Beery, E;Reshef, H;Sandbank, J;Birenbaum, M;Bakhanashvili, M;Yerushalmi, R;Luria, D;Lahav, M

文献摘要

参考文献

被引文献

相似文献

Imatinib mesylate (IM) is a tyrosine kinase inhibitor, which inhibits phosphorylation of downstream proteins involved in BCR-ABL signal transduction. It has proved beneficial in treating patients with chronic myeloid leukaemia (CML). In addition, IM demonstrates activity against malignant cells expressing c-kit and platelet-derived growth factor receptor (PDGF-R). The activity of IM in the blastic crisis of CML and against various myeloma cell lines suggests that this drug may also target other cellular components. In the light of the important role of telomerase in malignant transformation, we evaluated the effect of IM on telomerase activity (TA) and regulation in various malignant cell lines. Imatinib mesylate caused a dose-dependent inhibition of TA (up to 90% at a concentration of 15 μM IM) in c-kit-expressing SK-N-MC (Ewing sarcoma), SK-MEL-28 (melanoma), RPMI 8226 (myeloma), MCF-7 (breast cancer) and HSC 536/N (Fanconi anaemia) cells as well as in ba/F3 (murine pro-B cells), which do not express c-kit, BCR-ABL or PDGF-R. Imatinib mesylate did not affect the activity of other DNA polymerases. Inhibition of TA was associated with 50% inhibition of proliferation. The inhibition of proliferation was associated with a decrease in the S-phase of the cell cycle and an accumulation of cells in the G2/M phase. No apoptosis was observed. Inhibition of TA was caused mainly by post-translational modifications: dephosphorylation of AKT and, to a smaller extent, by early downregulation of hTERT (the catalytic subunit of the enzyme) transcription. Other steps of telomerase regulation were not affected by IM. This study demonstrates an additional cellular target of IM, not necessarily mediated via known tyrosine kinases, that causes inhibition of TA and cell proliferation.
DOI: 10.1038/sj.onc.1205076
发表时间: 2002-01-21
期刊: ONCOGENE
影响因子: 8
作者:
Harley, CB
通讯作者: Harley, CB
DOI: 10.1093/emboj/20.24.6958
发表时间: 2001-12-17
期刊: EMBO JOURNAL
影响因子: 11.4
作者:
Damm, K;Hemmann, U;Schnapp, A
通讯作者: Schnapp, A
DOI: 10.1038/sj.neo.7900112
发表时间: 2000-09-01
期刊: NEOPLASIA
影响因子: 4.8
作者:
Colgin, LM;Wilkinson, C;Reddel, RR
通讯作者: Reddel, RR
DOI: 10.1016/j.bcp.2003.06.001
发表时间: 2003-11-15
影响因子: 5.8
作者:
Bakalova, R;Ohba, H;Baba, Y
通讯作者: Baba, Y
DOI: 10.1182/blood.v96.3.925.015k50_925_932
发表时间: 2000-08-01
期刊: BLOOD
影响因子: 20.3
作者:
Heinrich, MC;Griffith, DJ;Zigler, AJ
通讯作者: Zigler, AJ